Medical nutrition market seen reaching $95.8B by 2035

Market Research Future projects the global medical nutrition market will nearly double from $49.8 billion in 2025 to $95.8 billion by 2035, driven by aging populations, chronic disease growth and more personalized clinical nutrition. North America leads today, while Asia-Pacific is set to grow fastest as hospitals and homecare settings expand use of enteral and parenteral nutrition.

Why it matters: - Medical nutrition is moving from a niche clinical support tool to a broader part of care for aging patients, people with chronic disease and patients recovering at home. - The market’s projected rise to $95.8 billion by 2035 signals continued demand for therapies that can shorten hospital stays, support recovery and improve quality of life. - Growth is tied to healthcare systems trying to manage complex conditions more cost-effectively and reduce readmissions.

What happened: - Market Research Future said the global medical nutrition market was valued at $46.6 billion in 2024. - The market is projected to grow from $49.8 billion in 2025 to $95.8 billion by 2035. - That implies a 6.8% compound annual growth rate from 2025 to 2035. - North America held the largest regional share in 2024. - Asia-Pacific is projected to be the fastest-growing region. - The research is available through a free sample, with detailed insights also published online.

The details: - Aging populations, rising chronic metabolic disease, cancer burden and new targeted clinical formulas are the main growth drivers. - Healthcare providers are expanding structured nutrition protocols across hospitals, long-term care, ambulatory centers and homecare settings. - Early nutritional risk screening and personalized therapeutic regimens are widening the market. - Product growth is led by pediatric nutrition, which held a dominant share in 2024. - Adult nutrition is expected to be a high-growth segment through 2035. - Gastrointestinal and specialized nutrition is expanding for malabsorption syndromes, inflammatory bowel disease and critical care support. - Oral nutrition solutions remain the leading route of administration. - Enteral nutrition is widely used in acute and homecare settings. - Parenteral nutrition serves patients with severely compromised gastrointestinal function. - Oncology is the dominant application area, driven by cancer cachexia and therapy tolerance needs. - Gastrointestinal disorders, neurological disorders and pediatric and metabolic conditions are also major uses. - Hospitals and ICU units generated the largest revenue share in 2024. - Homecare settings are the fastest-growing end-use category. - Long-term care and nursing facilities remain an established customer base. - Abbott Laboratories, Danone S.A. / Nutricia, Nestlé Health Science, Fresenius Kabi AG, B. Braun Melsungen AG, Baxter International Inc., Mead Johnson & Company, LLC and Perrigo Company plc are among the key companies named in the report. - Recent company activity highlighted by the report includes broader adult and pediatric portfolios at Abbott, oncology and dysphagia-focused nutrition at Danone, enteral and specialized clinical research at Nestlé Health Science, and new parenteral and enteral offerings at Fresenius Kabi and B. Braun.

Between the lines: - The market is shifting toward more personalized products, not just more products. - Biomarker tracking, metabolic profiling and digital clinical assessments are becoming important differentiators. - Homecare is emerging as a major commercial channel because it aligns with patient preference and cost-containment goals. - Regional differences matter: North America’s lead reflects reimbursement and infrastructure, while Asia-Pacific’s growth reflects access expansion and demographics.

What's next: - By 2035, the report expects medical nutrition to be more integrated into routine disease management. - Smart enteral feeding devices and connected monitoring systems are expected to improve adherence and remote management in homecare. - Manufacturers are likely to keep investing in disease-specific formulas for oncology, renal failure, pediatric metabolic disorders and other specialized needs. - Multi-functional formulas with anti-inflammatory, immune-modulating and gut-barrier support ingredients are expected to gain traction.

The bottom line: - Medical nutrition is set for steady, long-run growth as healthcare systems lean harder on targeted nutrition to manage chronic disease, aging and recovery.